https://www.esmo.org/The latest news from ESMOen-GBnoreply@esmo.orgMon, 09 Nov 2026 02:16:02 +0000Mon, 09 Nov 2026 02:16:02 +0000 Scientific News https://www.esmo.org/insights-by-esmo/all-news/how-to-select-adjuvant-endocrine-therapy-for-postmenopausal-women-with-hr-positive-early-breast-cancer<p><br></p>noreply@esmo.org1e699897-5ede-4fd2-bb94-cd7aae773e99Tue, 03 Nov 2026 09:06:00 +0000 Drug Approval https://www.esmo.org/insights-by-esmo/all-news/ema-recommends-extension-of-therapeutic-indications-for-abiraterone-acetate<p>New indications concern treatment of patients with newly diagnosed metastatic and non-metastatic hormone sensitive prostate cancer</p>noreply@esmo.org13a2ecb3-cb29-4e0c-a9a8-784ef90ac342Thu, 29 Oct 2026 08:00:00 +0000 Scientific News https://www.esmo.org/insights-by-esmo/all-news/esmo-and-asco-publish-joint-consensus-statement-on-streamlining-clinical-research<p><br></p>noreply@esmo.orgfb48ee36-bcd8-4586-90ad-dd3f94d139daWed, 28 Oct 2026 14:03:00 +0000 Drug Approval https://www.esmo.org/insights-by-esmo/all-news/fda-grants-accelerated-approval-to-camizestrant-with-a-cdk4-6-inhibitor-for-esr1-mutated-hr-positive-her2-negative-locally-advanced-or-metastatic-breast-cancer<p>Evidence for efficacy is based on the results from the<strong> </strong>SERENA-6 study</p>noreply@esmo.org9fc0c319-484e-44a9-b1a4-438cd8f0dfd6Wed, 28 Oct 2026 08:00:00 +0000 Opinion https://www.esmo.org/insights-by-esmo/all-news/non-pharmacological-interventions-are-they-important-to-patients-with-cancer<p><br></p>noreply@esmo.org24046734-2939-4382-90c8-4bfba90120a5Tue, 27 Oct 2026 07:12:00 +0000 Opinion https://www.esmo.org/insights-by-esmo/all-news/bringing-ai-to-the-data-the-future-of-privacy-compliant-cancer-research<p><br></p>noreply@esmo.org7b7f0f8e-cca1-4e71-ba2b-53f805ac7c72Tue, 27 Oct 2026 07:12:00 +0000 Scientific News https://www.esmo.org/insights-by-esmo/all-news/new-targeted-treatments-raise-the-bar-in-immunotherapy-resistant-melanoma<p><br></p>noreply@esmo.org471a4a02-d454-47e7-9ad5-6e28b6214a6eTue, 27 Oct 2026 07:11:00 +0000 Scientific News https://www.esmo.org/insights-by-esmo/all-news/detection-of-ctdna-fractions-with-a-single-tumour-informed-and-tumour-agnostic-profiling-assay-strongly-predicts-relapse-in-lung-cancer<p><br></p>noreply@esmo.orgcd78ae24-bfcc-4937-bb82-e0703246d393Tue, 27 Oct 2026 07:11:00 +0000 Scientific News https://www.esmo.org/insights-by-esmo/all-news/the-future-of-dmmr-msi-h-locally-advanced-rectal-cancer-could-be-free-from-chemotherapy<p><br></p>noreply@esmo.orge2fcf743-4ec2-4d13-8f74-f22e488fee47Tue, 27 Oct 2026 07:10:00 +0000 Scientific News https://www.esmo.org/insights-by-esmo/all-news/esmo-congress-2026-drives-global-dissemination-of-practice-changing-oncology-research<p><br></p>noreply@esmo.orgbaeab806-b29e-4a32-b342-49112d34fe86Tue, 27 Oct 2026 07:10:00 +0000 Scientific News https://www.esmo.org/insights-by-esmo/all-news/emactuzumab-reduces-tumour-size-in-patients-with-tenosynovial-giant-cell-tumours<p><br></p>noreply@esmo.orge990ae6f-8f11-403b-a41d-2b3d0891b851Tue, 27 Oct 2026 07:09:00 +0000 Scientific News https://www.esmo.org/insights-by-esmo/all-news/novel-t-cell-based-therapies-are-demonstrating-strong-and-durable-responses-in-solid-tumours<p><br></p>noreply@esmo.org7923a2e5-e9d8-42c6-b981-fcfa21fa7df1Tue, 27 Oct 2026 07:09:00 +0000 Scientific News https://www.esmo.org/insights-by-esmo/all-news/sacituzumab-tirumotecan-shows-significant-clinical-benefit-in-advanced-recurrent-endometrial-cancer<p><br></p>noreply@esmo.orgad70c958-6b81-4bf4-a60f-babf37d73d22Mon, 26 Oct 2026 16:42:00 +0000 Scientific News https://www.esmo.org/insights-by-esmo/all-news/de-escalating-immunotherapy-in-advanced-or-metastatic-cancer-it-is-not-time-yet<p><br></p>noreply@esmo.org41d67d8c-53f3-47e1-ad63-e2f14c4274d9Mon, 26 Oct 2026 15:54:00 +0000 Scientific News https://www.esmo.org/insights-by-esmo/all-news/osteosarcoma-first-progress-in-decades-with-an-antibody-drug-conjugate<p><br></p>noreply@esmo.org6545ded1-72e8-4341-bf40-2c8968a7130dMon, 26 Oct 2026 15:30:00 +0000 Editorial https://www.esmo.org/insights-by-esmo/all-news/the-sustainability-of-treatment-optimisation<p><br></p>noreply@esmo.org4f5bc115-b527-4088-b13a-1db428e1d03bMon, 26 Oct 2026 15:15:00 +0000 Scientific News https://www.esmo.org/insights-by-esmo/all-news/an-anti-claudin-18-2-antibody-drug-conjugate-prolongs-overall-survival-in-gastroesophageal-cancer<p><br></p>noreply@esmo.org06a113ff-5be2-47de-bab1-0385e0d302c8Mon, 26 Oct 2026 14:00:00 +0000 Opinion https://www.esmo.org/insights-by-esmo/all-news/a-new-era-for-ras-mutated-pancreatic-ductal-adenocarcinoma<p><br></p>noreply@esmo.orgf66c7dcd-4f90-401e-870a-c4ed122e9ba1Mon, 26 Oct 2026 13:45:00 +0000 Scientific News https://www.esmo.org/insights-by-esmo/all-news/targeted-and-cellular-therapies-open-promising-directions-in-sarcoma-treatment<p><br></p>noreply@esmo.org605eafb9-2e8b-4b25-8864-42f550cf77dfMon, 26 Oct 2026 13:45:00 +0000 Opinion https://www.esmo.org/insights-by-esmo/all-news/single-cell-and-spatial-profiling-hold-the-key-to-unlocking-tumour-complexity<p><br></p>noreply@esmo.org583df905-7f80-4a33-bbb4-1b56d67b1372Mon, 26 Oct 2026 13:45:00 +0000